Cargando…

Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach

BACKGROUND: The World Health Organization (WHO) currently recommends height or age-based dosing as alternatives to weight-based dosing for mass drug administration lymphatic filariasis (LF) elimination programs. The goals of our study were to compare these alternative dosing strategies to weight-bas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goss, Charles W., O’Brian, Katiuscia, Dubray, Christine, Fischer, Peter U., Hardy, Myra, Jambulingam, Purushothaman, King, Christopher L., Laman, Moses, Lemoine, Jean Frantz, Robinson, Leanne J., Samuela, Josaia, Subramanian, Swaminathan, Supali, Taniawati, Weil, Gary J., Schechtman, Kenneth B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663033/ https://www.ncbi.nlm.nih.gov/pubmed/31314753 http://dx.doi.org/10.1371/journal.pntd.0007541

Ejemplares similares

Country Reports on Practical Aspects of Conducting Large-Scale Community Studies of the Tolerability of Mass Drug Administration with Ivermectin/Diethylcarbamazine/Albendazole for Lymphatic Filariasis
por: Jambulingam, Purushothaman, et al.
Publicado: (2022)

The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study
por: Weil, Gary J., et al.
Publicado: (2019)

A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis
por: Krentel, Alison, et al.
Publicado: (2021)

Comparison of the Impact of Annual and Semiannual Mass Drug Administration on Lymphatic Filariasis Prevalence in Flores Island, Indonesia
por: Supali, Taniawati, et al.
Publicado: (2019)

Mapping and monitoring for a lymphatic filariasis elimination program: a systematic review
por: Srividya, Adinarayanan, et al.
Publicado: (2019)

Epidemiological Assessment of Eight Rounds of Mass Drug Administration for Lymphatic Filariasis in India: Implications for Monitoring and Evaluation
por: Swaminathan, Subramanian, et al.
Publicado: (2012)

Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study
por: Dubray, Christine L., et al.
Publicado: (2020)

Regulatory T Cells in Human Lymphatic Filariasis: Stronger Functional Activity in Microfilaremics
por: Wammes, Linda J., et al.
Publicado: (2012)

Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators
por: Jambulingam, Purushothaman, et al.
Publicado: (2016)

The Prevalence of Lymphatic Filariasis in Elementary School Children Living in Endemic Areas: A Baseline Survey Prior to Mass Drug Administration in Pekalongan District-Indonesia
por: GINANDJAR, Praba, et al.
Publicado: (2018)

Multicentre evaluations of two new rapid IgG4 tests (WB rapid and panLF rapid) for detection of lymphatic filariasis
por: Noordin, Rahmah, et al.
Publicado: (2007)

Molecular xenomonitoring as a post-MDA surveillance tool for global programme to eliminate lymphatic filariasis: Field validation in an evaluation unit in India
por: Subramanian, Swaminathan, et al.
Publicado: (2020)

A comparison of two tests for filarial antigenemia in areas in Sri Lanka and Indonesia with low-level persistence of lymphatic filariasis following mass drug administration
por: Yahathugoda, Thishan C., et al.
Publicado: (2015)

An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India
por: Jambulingam, Purushothaman, et al.
Publicado: (2021)

The Importance of Partnership in the Rollout of Triple-Drug Therapy to Eliminate Lymphatic Filariasis in the Pacific
por: Rainima-Qaniuci, Merelesita, et al.
Publicado: (2022)

Application of a household-based molecular xenomonitoring strategy to evaluate the lymphatic filariasis elimination program in Tamil Nadu, India
por: Subramanian, Swaminathan, et al.
Publicado: (2017)

Simulating the effect of evaluation unit size on eligibility to stop mass drug administration for lymphatic filariasis in Haiti
por: Kostandova, Natalya, et al.
Publicado: (2022)

Impact of Six Rounds of Mass Drug Administration on Brugian Filariasis and Soil-Transmitted Helminth Infections in Eastern Indonesia
por: Supali, Taniawati, et al.
Publicado: (2013)

MDA—Lymphatic Filariasis
por: Ichimori, Kazuyo
Publicado: (2014)

Urban lymphatic filariasis
por: Simonsen, Paul E., et al.
Publicado: (2012)

Mass Drug Administration for the Elimination of Lymphatic Filariasis — Port-au-Prince, Haiti, 2011–2012
por: Streit, Thomas, et al.
Publicado: (2013)

Development and Introduction of the Filariasis Test Strip: A New Diagnostic Test for the Global Program to Eliminate Lymphatic Filariasis
por: Pantelias, Anastasia, et al.
Publicado: (2022)

Geospatial modelling of lymphatic filariasis and malaria co-endemicity in Nigeria
por: Eneanya, Obiora A, et al.
Publicado: (2023)

Haiti National Program for the Elimination of Lymphatic Filariasis—A Model of Success in the Face of Adversity
por: Oscar, Roland, et al.
Publicado: (2014)

Mathematical models for lymphatic filariasis transmission and control: Challenges and prospects
por: Swaminathan, Subramanian, et al.
Publicado: (2008)

Lymphatic filariasis in Fiji: progress towards elimination, 1997–2007
por: Manolas, Rosie K., et al.
Publicado: (2020)

Endpoints for Lymphatic Filariasis Programs
por: Grady, Caroline A., et al.
Publicado: (2007)

Mapping of lymphatic filariasis in Nepal
por: Sherchand, Jeevan B, et al.
Publicado: (2003)

Elimination of Lymphatic Filariasis in The Gambia
por: Rebollo, Maria P., et al.
Publicado: (2015)

Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial
por: Tavul, Livingstone, et al.
Publicado: (2022)

Transmission Assessment Surveys (TAS) to Define Endpoints for Lymphatic Filariasis Mass Drug Administration: A Multicenter Evaluation
por: Chu, Brian K., et al.
Publicado: (2013)

Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin
por: Wilson, Nana O., et al.
Publicado: (2016)

Impact of annual and semi-annual mass drug administration for Lymphatic Filariasis and Onchocerciasis on Hookworm Infection in Côte d’Ivoire
por: Loukouri, Agodio, et al.
Publicado: (2020)

Positive-case follow up for lymphatic filariasis after a transmission assessment survey in Haiti
por: Hast, Marisa A., et al.
Publicado: (2022)

Risk factors for lymphatic filariasis in two villages of the Democratic Republic of the Congo
por: Chesnais, Cédric B., et al.
Publicado: (2019)

Polisye Kont Moustik: A Culturally Competent Approach to Larval Source Reduction in the Context of Lymphatic Filariasis and Malaria Elimination in Haiti
por: Bardosh, Kevin Louis, et al.
Publicado: (2017)

The history of the elimination of lymphatic filariasis in China
por: De-jian, Sun, et al.
Publicado: (2013)

Lymphatic Filariasis Disseminating to the Upper Extremity
por: Maldjian, Catherine, et al.
Publicado: (2014)

The burden of mental health in lymphatic filariasis
por: Ton, Thanh G.N., et al.
Publicado: (2015)

Environmental suitability for lymphatic filariasis in Nigeria
por: Eneanya, Obiora A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n1jdpretc64s60746hfr78q4es